All In Biotech

NDA 019386 · Baxter Hlthcare

Brevibloc

Esmolol Hydrochloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Dec 31, 1986

Approved uses

3

Original approval plus efficacy supplements

Registered trials

99

17 Phase 3, 7 recruiting

FAERS reports

267

251 serious, 46 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 6, 2026.

1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of BREVIBLOC injection to prevent such events is not recommended. BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: •Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia (1.1) •Control of perioperative tachycardia and hypertension (1.2)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 1992 Supplement 3 · Efficacy
  • Dec 18, 1992 Supplement 8 · Efficacy
  • Dec 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review Review
6 products under this application
  • BREVIBLOC · ESMOLOL HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • BREVIBLOC IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 1GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • BREVIBLOC · ESMOLOL HYDROCHLORIDE 250MG/ML · INJECTABLE, INJECTION · Discontinued
  • BREVIBLOC · ESMOLOL HYDROCHLORIDE 20MG/ML · INJECTABLE, INJECTION · Discontinued
  • BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 2GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • BREVIBLOC · ESMOLOL HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Esmolol" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective36
  • cardiac arrest21
  • hypotension20
  • bradycardia17
  • product use issue15
  • product use in unapproved indication12
  • renal failure10
  • ventricular fibrillation10
  • hypertension9
  • acute kidney injury8
  • atrial fibrillation8
  • death8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20056
20065
20077
20084
200910
20106
201114
20126
20139
20147
201521
201617
201710
201815
201914
202013
202116
202214
202321
202411
202526
20269

Recalls

2 FDA enforcement reports for this application.

  • Apr 12, 2016 · Class II · Terminated

    Discoloration: presence of atypical yellow discoloration of the solution .

  • Jun 16, 2014 · Class II · Terminated

    Presence of Particulate Matter: Complaints received of discolored solution identified as subvisible particles of iron oxide that are agglomerating.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Brevibloc* (Esmolol HCL*) · HCPCS J1805

2024 spending

$73K

Beneficiaries

6,530

7,479 claims

Per beneficiary

$11

2024 ASP limit $0.23 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$37
2024$72,801

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 395 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Brevibloc In Plastic Container, Brevibloc Double Strength In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.